BRUSSELS, Feb 5 (Reuters) - Belgian biotech companyGalapagos said on Tuesday that its partnerGlaxoSmithKline (GSK) planned to start Phase II studiesinto a drug candidate to treat two auto-immune disorders.
Galapagos said in a statement that GSK would launch thestudies for compound GSK2586184 in systemic lupus erythematosus(SLE) and chronic plaque psoriasis.
Galapagos is eligible to receive 34 million euros inadditional milestones plus up to double-digit percentageroyalties on global sales. It is the second selective JAK1molecule discovered by Galapagos to enter Phase 2 studies.
Glaxosmithkline (GSK)